| Document |
Document Title |
|
WO/2003/072597A1 |
More efficient and/or economical methods for synthesizing heptap eptide alcohol analogs of oxytocin are provided along with novel intermediates which are useful in synthesizing such oxytocin analogs. Efficient and economical methods for ...
|
|
WO/2003/070675A2 |
This invention provides a compound, or its possible salt, having the formula, wherein: Re and 'Re are OH, optionally independently etherified or esterified&semi Z is −CH2CH2− or −C(R4,R5)− , wherein R4 and R5 are independently H,...
|
|
WO/2003/069995A1 |
Disclosed are new microbicidal agents on the basis of biphenyl benzamide derivatives of general formula (I), in which R1, R2, R3, and m have the meanings indicated in the description, and new biphenyl benzamides, several methods for prod...
|
|
WO/2003/070696A2 |
The invention relates to novel substituted aryl ketones of formula (I), in which Z, X, R and n have the meanings as cited in the description. The invention also relates to a method for producing these substituted aryl ketones, to their u...
|
|
WO/2003/068913A2 |
The present invention is directed to labeled compounds, [2-13C]dithiane wherein the 13C atom is directly bonded to one or two deuterium atoms. The present invention is also directed to processes of preparing [2-13C]dithiane wherein the 1...
|
|
WO/2003/068721A1 |
The invention relates to a continuous method for the purification of acrolein, wherein: an aqueous acrolein solution is supplied, devoid of gas which is difficult to condense, in a distillation column fitted with at least one boiler at t...
|
|
WO/2003/067332A2 |
Chemically amplified photoresist compositions comprising, (a) a compound which cures upon the action of an acid or a compound whose solubility is increased upon the action of an acid&semi and (b) a compound of the formula (Ia), (Ib), (II...
|
|
WO/2003/066582A1 |
A process for the preparation of highly pure 1-(mercaptomethyl)-cyclopropaneacetic acid is described. Treatment of 1-(hydroxymethyl)-cyclopropaneacetonitrile with an acid provides the corresponding imino ester and/or halo-amide, which wh...
|
|
WO/2003/066035A2 |
Compounds, compositions and methods for altering insulin secretion, particularly in the context of treatment of subjects having, or suspected of being at risk for having, diabetes mellitus. The compounds have the following struture (I): ...
|
|
WO/2003/064369A1 |
It is intended to provide compounds represented by the following general formula (I) which have a high affinity for human thyroid hormone receptors, in particular, human thyroid hormone receptor β, medicinal compositions containing the ...
|
|
WO/2003/063797A2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating dela...
|
|
WO/2003/062191A1 |
The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.
|
|
WO/2003/061595A2 |
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo to amphetamines are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. A therapeutic composition co...
|
|
WO/2003/059875A2 |
Formula (I) compounds are described in which the substituents have the meanings described in the text, and which are useful for the treatment of diseases responding to PPAR$g(a) activation, such as heart failure, the hyperlipaemias and a...
|
|
WO/2003/059064A1 |
Insecticides containing as the active ingredient hydrazone derivatives represented by the general formula (I); and novel hydrazone derivatives: (I) wherein A and Q are each aryl or a heterocyclic group; W is oxygen, aminylene, alkylene, ...
|
|
WO/2003/059874A2 |
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula (I) and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeuticall...
|
|
WO/2003/060523A1 |
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NA...
|
|
WO/2003/059866A1 |
Compounds represented by the general formulae (I-1), (I-2), (I-3) and (I-4) and having excellent antitumor activity: (I-1) (I-2) (I-3) (I-4) wherein R1, R2, R3, m, n and R4 are each as defined in the description.
|
|
WO/2003/059873A1 |
This invention relates to novel compounds characterized by the general Formula (I) any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, or an N-oxide thereof, useful as potassium channe...
|
|
WO/2003/055848A2 |
This invention relates to urea derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof: (I) wherein Y is R1- R6 and X have the same meanings given in the description, which is useful as an active ingredie...
|
|
WO/2003/055847A1 |
A compound which is useful as a VEGF receptor antagonist and has excellent properties. It is a carboxylic acid derivative represented by the formula (1) [wherein ring A represents a benzene ring, naphthalane ring, etc.; W represents C1-5...
|
|
WO/2003/055852A2 |
The invention relates to compounds of formula (I), wherein Z represents a hydrocarbon with 2 to 28 C atoms, wherein Z can also comprise elements N, O, P, S, Si and halogen as heteroatoms, R1 and R2 are identical or different sulfur prote...
|
|
WO/2003/055850A1 |
Novel compounds having an effect of inhibiting the production/secretion of a β-amyloid protein. Namely, compounds having various substituents as represented by the following general formula (1), salts thereof and solvates of the same: (1)
|
|
WO/2003/053890A1 |
The invention provides a mixed heteroatomic ligand for an oligomerisation of olefins catalyst, which ligand includes at least three heteroatoms, of which at least one heteroatom is sulfur and at least 2 heteroatoms are not the same.The i...
|
|
WO/2003/053912A1 |
There is provided a series of novel $g(a)-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R?1¿, R?2¿ and R?3¿ are defined herein, which are inhibitors of $g(b)-amyloid peptide ($g(b)-AP) production and are useful in t...
|
|
WO/2003/053915A2 |
This invention relates to compounds of the Formula (I):(Chemical formula should be inserted here as it appears on abstract in paper form)(I)or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the tre...
|
|
WO/2003/053974A1 |
The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically ac...
|
|
WO/2003/053910A1 |
It is intended to provide a stable isotope-labeled amino acid which is at least one of amino acids constituting protein, characterized by having at least one of the following labeling patterns: (a) in one or more methylene groups, methyl...
|
|
WO/2003/053891A1 |
The invention provides a mixed heteroatomic ligand for an oligomerisation of olefins catalyst, which ligand includes at least three heteroatoms, of which at least one heteroatom is nitrogen and at least two heteroatoms are not the same.T...
|
|
WO/2003/051826A1 |
A compound of formula (I); wherein R1 represents chloro, fluoro or hydroxy as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, to processes for ...
|
|
WO/2003/051807A2 |
Compounds of formulae (I) or (II): wherein R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton, and R1 and R2 a...
|
|
WO/2003/051841A2 |
Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone ...
|
|
WO/2003/051842A2 |
Carbamates and related compounds of formula R1R2NCO-Y or R1R2NCS-Y wherein R1 and R2 may form a ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasm...
|
|
WO/2003/051823A1 |
β-Amino-&agr -Cyanoacrylates of formula I where the variables have the following meanings: R1 is n-alkyl, n-alkenyl or alkoxyalkyl; R2,R3 are alkyl, which may be partially or fully halogenated and/or may carry a substituent from the gro...
|
|
WO/2003/051893A2 |
Compounds of formula (I) or (II), wherein R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton, and R1 is a subs...
|
|
WO/2003/051827A1 |
The invention relates to a process for the preparation of an enantiomerically enriched compound of formula (1) or a salt thereof, in which R?1¿ and R?2¿ each independently represent an (hetero)alkyl or (hetero)aryl group, wherein R?1¿...
|
|
WO/2003/051348A2 |
This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antago...
|
|
WO/2003/050071A1 |
The invention relates to a process for the preparation of methionine of high bulk density, in which a mixture which comprises a compound which has a foaming action and a compound which influences the crystallization is added to the hydro...
|
|
WO/2003/049666A2 |
The present invention relates to the field of perfumery. More particularly, it concerns compounds comprising at least one $g(b)-oxy or $g(b)-thio carbonyl moiety capable of liberating a perfuming molecule such as, for example, an $g(a),$...
|
|
WO/2003/050073A1 |
Disclosed are compounds of the formula (I) and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R3, R4, R5, RN, and RC are defined herein. These compounds interact with and inhibit the activity of th...
|
|
WO/2003/049702A2 |
Compounds having the general structure of the Formula (I) and compositions containing them, for treatment of various diseases.
|
|
WO/2003/048109A1 |
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
|
|
WO/2003/048112A1 |
The invention relates to compounds of the general formula (I), in which R¿1?, R¿2?, X, Ar¿1? and Ar¿2? are as defined in claim 1, and to any enantiomers thereof. The active ingredients have advantageous pesticidal properties. They ar...
|
|
WO/2003/046200A2 |
The present invention provides novel methods for ligand discovery. The inventive methods rely on a process termed 'tethering' where potential ligands are covalently bonded or 'tethered' to a target and subsequently identified as exemplif...
|
|
WO/2003/045904A1 |
The invention aims at providing a process by which high-quality crystals of methionine in the form of granules or thick plates having high bulk density can be stably produced. The aim can be attained by a process for production of methio...
|
|
WO/2003/043624A1 |
Compounds that are dual aP2/k-FABP inhibitors are provided having the formula (I), wherein A, B, X, Y, R?1¿, R?2¿ and R?3¿ are as described herein. A method is also provided for treating diabetes and related diseases, especially Type ...
|
|
WO/2003/042164A1 |
The invention provides novel $g(b)¿2? adrenergic receptor agonist compounds of formula (I): wherein R?1¿-R?13¿ and w have any of the values described in the specification. The invention also provides pharmaceutical compositions compri...
|
|
WO/2003/042168A1 |
The invention relates to &agr -oxygenated or &agr -thiolated carboxylic acid phenethylamide derivatives of general formula (I) including the optical isomers thereof and mixtures of such isomers, wherein A stands for optionally substitute...
|
|
WO/2003/042163A1 |
Disclosed is the synthesis of N-methyl-homocystines and the use thereof.
|
|
WO/2003/042153A1 |
A pest control agent which is highly effective in pest control and is highly safe for crops, natural enemies to pests, and mammals. It is a difluoroalkene derivative represented by the following general formula [1] or a pharmacologically...
|
